Searched for
GILEAD DRUG PATENT
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipelineGilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...- Activists sound alarm bells as Gilead seeks rights over HIV drugLenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears Gilead's patent ...
- How a drug major profited by slow-walking a promising HIV therapyToday, a generation of expensive Gilead drugs containing the new iteration of tenofovir account for half of the market for HIV treatment an...
- NPPA seeks clarification on Gilead's drug pricing pleaNational Pharmaceutical Pricing Authority has sought clarifications from the company. Gilead had sought exemption from price control for it...
- Merck wins record $2.5 billion patent verdict against GileadThe judge in the case had already decided that Merck’s patent was infringed by Gilead’s Sovaldi and Harvoni, which account for more than ha...
- Gilead Sciences withdraws writ petition in support of consolidating hearings over patent rightsLegal experts questioned Gilead's decision to take up the matter at the Delhi HC, saying it ought to have directly approached the Kolkata P...
- Government's patent grant to Gilead challenged in Delhi High CourtGilead has claimed existing public knowledge as its own and its patent on sofosbuvir, the base compound in its HepC drug Sovaldi, is "unmer...
- Gilead’s $1,000 pill gets patent in IndiaGilead's patent application was first rejected - just before President Obama's visit in 2015 January - which was seen to be upsetting the U...
- Natco Pharma launches hepatitis C drug in NepalThe drug launched under the brand name Hepcinat is priced at Rs 19,900, or roughly $300 for 28 tablets, Natco said in its communication to ...
- Patent row no hurdle for Gilead Pharma’s Sovaldi launchGilead Pharma says that the recent decision by the patent office, which rejected patent for one of its molecules, does not impact its India...
- Gilead to challenge hepatitis C drug patent rejection decision"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.
- US group seeks to block Gilead drug patent in India"India's patent law doesn't give monopolies for old science or for compounds already in the public domain," Tahir Amin, director of I-MAK s...
- Gilead Sciences Inc allows 4 Indian pharmaceutical companies Ranbaxy Laboratories, Matrix Laboratories, Hetero Drugs and Strides Arcolab to sell HIV GenericsRanbaxy Laboratories, Matrix Laboratories, Hetero Drugs and Strides Arcolab can make and sell the three drugs in 100 countries by paying ro...
- US' Gilead appeals against patent rejection of AIDS drug VireadUS drug company Gilead Sciences has filed an appeal in the Indian Intellectual Property Appellate Board (IPAB) to challenge a recent order ...
- Gilead’s Hepatitis patent plea rejectedThe Delhi Patent Office has rejected American company Gilead Sciences’ plea to patent its Hepatitis B drug adefovir dipivoxil sold under th...
- New Delhi rejects American firm's plea to patent Hepatitis B drugThe Delhi Patent Office has rejected American company Gilead Sciences’ plea to patent its Hepatitis B drug adefovir dipivoxil sold under th...
- Cipla on firm ground in patent challengeIn what could strengthen Cipla's patent challenge against global major Gilead Science's patent application for its key HIV drug, Viread, th...
- Anti-AIDS blitz sees pharma firms locked in ugly battleIt has now emerged that Aids Healthcare Foundation (AHF), the US-based NGO that accused Cipla of over pricing anti-AIDS drug, Viraday, in I...
- Aids drug prices to fall if Gilead fails to defend patent applicationPrice of a crucial AIDS drug may fall further if Cipla and AIDS patients succeed in their challenge to a patent application filed here by U...
- Cipla lends support to anti-patent driveDomestic pharma major Cipla is opposing US-based biotech major Gilead Sciences’ patent application in India for anti-AIDS drug Viread.
Load More
